TAVI

What Is Transcatheter Aortic Valve Replacement (TAVR)?

Transcatheter aortic valve replacement (TAVR) is a procedure that implants a new aortic valve inside your own narrowed valve, delivered through a thin tube called a catheter rather than through open-heart surgery. It treats severe aortic stenosis — a stiffened, usually calcified aortic valve that restricts blood flow out of the heart — and it is most often considered for older adults and for patients whose overall health makes conventional surgery higher risk. In the UK, Europe and much of the world, the same procedure is known as TAVI, or transcatheter aortic valve implantation.

To understand what the procedure does, it helps to know where the aortic valve sits. It lies between the left ventricle, the heart’s main pumping chamber, and the aorta, the large artery that carries oxygen-rich blood to the body. In aortic stenosis, this valve becomes narrowed, most often because calcium builds up on the valve leaflets over years. Instead of opening freely with each heartbeat, the valve becomes stiff and restricted. Blood flow is limited, pressure builds inside the heart, and the heart muscle must work progressively harder to push blood forward.

During TAVR, the replacement valve is compressed onto a catheter and advanced through a blood vessel, most often from the femoral artery in the groin. Once the valve is positioned precisely inside the diseased aortic valve, it is expanded. The new valve pushes the narrowed leaflets aside and begins working immediately, allowing blood to flow more easily from the heart to the rest of the body. There is no need to remove the old valve; the new one anchors within it.

TAVR is described as minimally invasive because it usually avoids opening the chest and does not typically require stopping the heart or using a heart-lung machine. Many patients are treated under conscious sedation, where you are relaxed but not fully asleep; others receive general anaesthesia, depending on the clinical situation and the team’s assessment. One caution is worth stating plainly: minimally invasive does not mean minor. TAVR is an advanced structural heart intervention. Its safety depends on accurate diagnosis, careful patient selection, precise imaging, and an experienced, coordinated team — not on the small size of the incision.

What does the TAVR medical abbreviation stand for?

The TAVR medical abbreviation stands for transcatheter aortic valve replacement. Each part of the name describes the procedure. “Transcatheter” means the new valve travels to the heart through a catheter inside a blood vessel, rather than through a surgical opening in the chest. “Aortic valve” identifies which of the heart’s four valves is being treated. “Replacement” describes the outcome: a new bioprosthetic valve, usually made from treated animal tissue mounted on a metal frame, takes over the work of the diseased valve. You may see the abbreviation written with or without full stops, but it always refers to the same catheter-based valve procedure.

Is there a difference between TAVR and TAVI?

No. TAVR and TAVI describe exactly the same procedure, and the terms are used interchangeably. TAVI — transcatheter aortic valve implantation — is the older and more widely used name in Europe, the UK and much of the world, and it is technically precise: the new valve is implanted inside the old one, which is not removed. TAVR — transcatheter aortic valve replacement — became the standard term in the United States, emphasising that the new valve replaces the function of the diseased one. If your cardiologist in one country recommends TAVI and a hospital abroad describes TAVR, you are reading about the same treatment. Throughout this page, the two terms are used according to context; nothing clinical changes with the name.

When Aortic Stenosis Becomes a Treatment Decision

Being told that your aortic valve is severely narrowed can feel unsettling, especially if you have already been living with shortness of breath, chest pressure, dizziness, or a gradual loss of energy. Many patients describe the same pattern: activities that once felt ordinary — walking uphill, climbing stairs, travelling, carrying groceries — begin to feel increasingly difficult. For some, the diagnosis follows a fainting episode or a heart murmur picked up during a routine examination. For others, it is found while being assessed for an entirely different medical problem.

Aortic stenosis is not simply a sign of ageing. It is a structural heart valve disease that places real strain on the heart. When the valve between the heart’s main pumping chamber and the aorta becomes stiff or narrowed, the heart must work harder with every beat. Over time, this can lead to worsening symptoms, reduced heart function, heart failure, and other serious complications. The narrowing itself does not reverse; once the disease is severe and symptomatic, the underlying mechanical problem needs a mechanical solution.

For many years, replacing the aortic valve required open-heart surgery: opening the chest, stopping the heart, and sewing in a new valve while a heart-lung machine took over circulation. That operation remains an excellent option for many patients, and it is still the preferred approach in certain anatomies and age groups. But today, selected patients can be treated with TAVI instead — a catheter-based alternative that replaces the diseased valve without traditional open-heart surgery in most cases. This matters most for older adults and for patients whose lungs, kidneys, previous operations or frailty make conventional surgery a heavier burden to carry.

The decision between TAVR, surgical valve surgery and continued monitoring is rarely obvious from a single test. It rests on how severe the stenosis is, whether symptoms are present, what the anatomy allows, and what the patient’s overall health and preferences support. That is why the assessment is structured, and why it involves more than one specialty.

Who May Need the TAVI Aortic Valve Procedure

The TAVI aortic valve procedure is considered for patients with severe aortic stenosis, particularly when symptoms are present or when heart testing shows that the valve disease is placing significant strain on the heart. The decision is never based on symptoms alone. Some patients reduce their activity so gradually that they do not realise how limited they have become. Others feel relatively well but show concerning findings on echocardiography — a weakening heart muscle, rising pressures, or a valve opening that has narrowed past the threshold where watchful waiting is safe.

TAVI is most often considered for patients who are older, medically complex, or at increased risk from open-heart surgery. This includes patients with previous cardiac surgery, lung disease, kidney disease, frailty, reduced heart function, or other conditions that raise surgical risk. In some situations, TAVI may also be an option for patients at lower surgical risk, depending on valve anatomy, age, expected valve durability, patient preference, and current guideline-based recommendations. Younger patients with long life expectancy raise particular questions about how long a transcatheter valve will last and what future procedures might be needed, which is one reason the choice between TAVI and surgery is individualised rather than automatic.

What symptoms lead to a TAVI assessment?

The symptoms that most commonly trigger evaluation are shortness of breath on exertion, chest pain or pressure, fatigue, dizziness, fainting, palpitations, swelling in the legs, and a shrinking capacity for exercise. Some patients develop episodes of heart failure: breathlessness when lying flat, sudden night-time shortness of breath, or fluid retention. In advanced disease, symptoms may occur with minimal activity or even at rest. Because these complaints overlap with lung disease, anaemia, deconditioning and ordinary ageing, part of the assessment is confirming that the valve — and not something else — is the main cause of how you feel.

How is severe aortic stenosis diagnosed?

Diagnosis usually begins with a clinical examination and a heart ultrasound called an echocardiogram. This test measures how narrow the valve is, how well the heart is pumping, and how much pressure is building across the valve. It is the cornerstone of the diagnosis and the main tool for grading severity. Additional tests may include electrocardiography, blood tests, chest imaging, coronary angiography, cardiac computed tomography, and assessments of kidney function, lung health, frailty, and other medical conditions.

A detailed CT scan is particularly important once TAVI is being planned. It measures the aortic valve opening, the size of the valve ring (the annulus), the shape of the aortic root, the position of the coronary arteries, and the condition of the arteries that would carry the catheter to the heart. These measurements determine which valve size fits your anatomy and which access route is safest. TAVI is a procedure planned in millimetres; the CT scan is where that planning starts.

The most appropriate treatment is then determined through a heart team evaluation. This typically brings together interventional cardiologists and specialists in cardiovascular surgery, supported by cardiac imaging specialists, anaesthesiologists, and other physicians as needed. The question the team asks is not simply whether TAVI can be done, but whether it is the best option for this particular patient compared with surgical valve replacement, medical management, or continued surveillance.

Conditions the TAVI Procedure Treats

The primary indication for the TAVI procedure is severe aortic valve stenosis, most often caused by age-related calcification of the valve. As calcium deposits accumulate, the leaflets become rigid and cannot open normally. This process is common in older adults, but its timing and severity vary widely from person to person; some people develop severe narrowing years earlier than others with no obvious explanation.

TAVI may also be considered in selected patients with a narrowed bicuspid aortic valve — a valve that formed with two leaflets instead of the usual three. Bicuspid anatomy is more complex for a transcatheter valve: the opening may be asymmetric, the calcium heavily and unevenly distributed, and the aorta itself may be enlarged. None of these features automatically rules out TAVI, but each demands careful imaging and specialist review before the procedure is judged suitable. In some bicuspid patients, surgery remains the sounder choice.

A third scenario is valve-in-valve TAVI, in which a transcatheter valve is implanted inside a surgical bioprosthetic valve placed years earlier that has since deteriorated. For selected patients who have already been through open-heart valve surgery and now face renewed narrowing or leakage, this can avoid a repeat operation. Whether it is feasible depends on the size and type of the original prosthesis, the position of the coronary arteries relative to it, and what future procedures might still be needed over the patient’s lifetime.

Some patients have mixed aortic valve disease — both narrowing and leakage at the same time. TAVI is designed primarily to treat stenosis, but it may be considered when stenosis is the dominant problem and the anatomy is appropriate. Pure aortic regurgitation, where the valve leaks but is not significantly narrowed or calcified, is a different situation: the standard devices anchor in calcium, and a valve without it gives them little to grip. Such cases require separate assessment and are not always suitable for standard TAVI techniques.

Finally, TAVI becomes especially relevant when severe aortic stenosis is driving heart failure symptoms, shrinking exercise tolerance, or causing repeated hospital admissions. It may also be evaluated before other major treatment — cancer surgery, for example — because an untreated severely narrowed valve raises the risk of procedures that have nothing to do with the heart.

How the TAVR Procedure Is Performed

The TAVR procedure begins well before the day of treatment. The first step is confirming that the aortic stenosis is genuinely severe and that valve replacement is medically appropriate. Patients are assessed with echocardiography, CT imaging, blood tests, heart rhythm evaluation and, when indicated, coronary angiography to check for blockages in the heart arteries that might need treatment before or alongside the valve. The team also reviews medications, allergies, prior procedures, kidney function, neurological history, and bleeding risk.

For international patients, this review can start remotely with medical records, imaging reports, echocardiography results, angiography images, laboratory tests, and physician summaries. Once you arrive, some testing may be repeated or added to confirm findings and finalise the plan. This is not bureaucracy — TAVI depends on exact anatomical measurements and on your current clinical status, and old or incomplete imaging is a poor foundation for a millimetre-level plan.

Before the procedure, the care team explains the planned access route, the anaesthesia approach, the monitoring you can expect, the possible risks, and the recovery process. Blood-thinning medication is reviewed by the treating team as part of this preparation. You will usually be asked not to eat or drink for a period beforehand. If there are dental infections, active infections elsewhere in the body, or unstable medical issues, these may need to be addressed before a valve is implanted, because infection around a new heart valve is a complication worth every effort to prevent.

Most procedures use the transfemoral approach: the catheter enters through an artery in the groin. This route is preferred when the leg and pelvic arteries are large enough and healthy enough to allow safe passage of the delivery system. When they are not — because of narrowing, tortuosity or heavy calcification — alternative access routes may be considered, chosen according to your anatomy and the experience of the heart team.

On the day itself, you are brought to a specialised cardiac catheterisation laboratory or hybrid operating environment equipped for structural heart procedures. A typical implantation follows this sequence:

1. Monitoring and anaesthesia. Heart rhythm, blood pressure and oxygen levels are continuously tracked. You receive conscious sedation or general anaesthesia, depending on the plan agreed beforehand.
2. Vascular access. Small tubes (sheaths) are placed into the blood vessels, usually in the groin, under imaging guidance.
3. Temporary pacing. A thin pacing wire may be positioned to control the heart rhythm briefly during the key moments of implantation.
4. Valve delivery. The compressed replacement valve is advanced through the catheter toward the heart, guided by fluoroscopy — real-time X-ray imaging — and echocardiography.
5. Preparation of the native valve. In some patients, the narrowed valve is first gently expanded with a balloon; in others, the new valve is positioned and deployed directly.
6. Implantation. The new valve is expanded inside the diseased one, anchoring in place and taking over immediately.
7. Verification. The team checks valve function, blood flow, pressure measurements, and whether there is any leakage around the valve. Adjustments are made if needed.
8. Closure and transfer. The access site is closed, and you move to a recovery area, intensive care unit, or monitored cardiac unit according to your condition and the hospital’s protocol.

The technology surrounding TAVR exists to reduce avoidable uncertainty, not to impress. High-resolution CT maps the valve and vessels before treatment. Echocardiography evaluates valve function and heart performance. Angiographic imaging provides live guidance during implantation. Continuous haemodynamic monitoring lets the team respond quickly to rhythm changes, blood pressure shifts, or access-site concerns. Every element is there to match the treatment to your anatomy.

The procedure itself often takes one to two hours, though the total time in the procedure area is longer because of preparation and post-procedure checks. Complex anatomy, additional coronary work, vascular challenges or medical instability can extend it. Early recovery focuses on heart rhythm monitoring, blood pressure control, access-site observation, kidney function, mobility, and neurological checks. Discomfort after TAVI is usually modest compared with open surgery, and it is actively managed — the approach is described in the guide to how pain is controlled after surgery and invasive procedures.

One outcome deserves specific mention: some patients need a permanent pacemaker after TAVI. The replacement valve sits close to the heart’s electrical wiring, and in some anatomies the implant presses on it. The likelihood varies with pre-existing conduction abnormalities, valve type and implantation depth, which is one reason rhythm monitoring continues after the procedure. Many patients are encouraged to sit, stand and walk soon after treatment, once the access site is stable and the team approves. Hospital stay is often shorter than after open-heart surgery, but the exact length depends on age, frailty, heart rhythm, kidney function, recovery pace, and whether anything additional needs treating. Discharge planning covers medication instructions, wound care, activity guidance, warning signs to be aware of, and follow-up appointments.

Is a TAVR considered major surgery?

TAVR is a major cardiac procedure, but it is not open surgery in the traditional sense. There is no chest incision, the heart is not stopped, and a heart-lung machine is not normally used — the work is done from inside the blood vessels. In that respect it sits between a standard catheter procedure, such as a coronary stent, and open-heart valve surgery. What makes it “major” is not the incision but the stakes: a new valve is being implanted in the outflow of the heart, and the preparation, imaging, team and backup required reflect that. It deserves the same seriousness of planning as an operation, even though the physical recovery is usually lighter.

How serious is TAVR surgery?

TAVR surgery — more accurately, the TAVR intervention — is a serious procedure with real risks, and an honest page should say so. Possible complications include bleeding or injury at the vascular access site, stroke, heart rhythm disturbances requiring a pacemaker, leakage around the new valve, kidney strain from contrast dye, and, rarely, the need for emergency surgery. The purpose of the extensive pre-procedure imaging, the heart team review and the monitored recovery is precisely to anticipate and reduce these risks for each individual anatomy. For most appropriately selected patients, the burden of the procedure is considerably lighter than open-heart surgery — but the decision to proceed is always a weighing of risks against the well-documented dangers of leaving severe symptomatic aortic stenosis untreated.

Why Acting Early Matters

Severe aortic stenosis can remain stable for a time, but once symptoms develop, the condition tends to progress in a way that significantly affects survival and quality of life if left untreated. The narrowed valve forces the heart to pump against high resistance. Over time, the heart muscle may thicken, stiffen, weaken, or become unable to meet the body’s needs — and some of that damage is harder to undo the longer it accumulates.

Delaying evaluation raises the risk of heart failure, fainting, abnormal heart rhythms, pulmonary hypertension, and shrinking functional capacity. Many patients adapt by simply doing less, which quietly masks the seriousness of the condition. A person may believe they are “just getting older” when, in fact, the valve is limiting blood flow with every beat.

Early assessment does not always mean immediate intervention. Some patients are monitored closely until the stenosis reaches a threshold where treatment is warranted. However, once severe symptomatic aortic stenosis is confirmed, timely valve replacement is usually recommended unless there are specific reasons it would not be appropriate. The earlier a heart team understands the full picture, the better it can plan treatment before a crisis forces the decision.

For patients travelling for care, timing matters for practical reasons too. Records may need translation or review, imaging may need repeating, and medication plans may need adjustment by the treating team before the procedure. Planning ahead allows a safer and more organised experience than waiting until symptoms become urgent.

Benefits of TAVI

For appropriately selected patients, TAVI can offer important clinical and practical advantages compared with living with untreated severe aortic stenosis, and a lighter physical burden than more invasive surgery. What each benefit means in practice:

Benefit	What It Means for You
Improved blood flow through the aortic valve	The new valve can relieve the obstruction, allowing the heart to pump blood more effectively to the body.
Less invasive approach	Most procedures are performed through an artery in the groin, usually without opening the chest or using traditional open-heart surgery.
Shorter early recovery for many patients	Selected patients may walk soon after the procedure and leave the hospital sooner than is typical after surgical valve replacement.
Symptom relief	Many patients experience less shortness of breath, improved stamina, and better ability to perform daily activities after recovery.
Option for higher-risk surgical patients	TAVI may make valve replacement possible for patients who face increased risk with open surgery because of age, frailty, or other medical conditions.
Team-based decision-making	Evaluation by cardiology, cardiac surgery, imaging, anaesthesia, and other specialists helps determine whether TAVI is the right approach for your anatomy and health status.

Two honest caveats belong alongside this list. First, these benefits apply to appropriately selected patients — anatomy and overall health decide who those are, not preference alone. Second, symptom relief depends on the valve being the true cause of the symptoms; where lung disease or other conditions contribute, they need their own treatment.

Recovery Timeline After TAVI

Recovery varies with age, baseline health, heart function, access route, and whether any rhythm or vascular issues arise, but many patients follow a broadly similar pattern:

Time Period	What Patients Can Expect
Day 1	Close monitoring of heart rhythm, blood pressure, access site, kidney function, and neurological status. Some patients begin sitting up and walking with assistance.
First Week	Gradual increase in walking and daily activity. Mild groin tenderness or bruising may occur. Medication instructions and follow-up plans are reviewed before travel or discharge.
First Month	Energy and breathing often improve progressively. Patients usually avoid heavy lifting and strenuous exertion until cleared by their physician. Follow-up testing may include echocardiography and rhythm assessment.
Longer Term	Ongoing cardiology follow-up to monitor valve function, medications, blood pressure, and overall heart health. Cardiac rehabilitation may be recommended for selected patients.

For patients who have travelled for treatment, the return journey is part of the recovery plan rather than an afterthought. When it is safe to board a flight depends on rhythm stability, access-site healing, medication needs and flight duration; the general principles are set out in the guide on flying after surgery, procedure by procedure. Some patients can return home relatively soon after discharge; others are advised to remain nearby for additional monitoring first.

What is the life expectancy after a TAVR?

There is no single life expectancy figure after TAVR, because outcomes depend heavily on the individual: age at treatment, heart function before the procedure, kidney and lung health, frailty, and how well other conditions are managed afterwards. What can be said honestly is this: untreated severe symptomatic aortic stenosis carries a serious outlook, because the heart cannot indefinitely sustain the workload the narrowed valve imposes. Replacing the valve removes that obstruction, and many patients go on to live active lives limited more by their general health than by their aortic valve. Transcatheter valves are bioprosthetic tissue valves, so their durability is monitored over the years with regular echocardiography, and long-term follow-up with a cardiologist remains part of life after the procedure. Your own heart team, who know your test results, is the right source for a personalised discussion of prognosis.

Factors That Influence Outcomes

A good TAVI result depends on much more than placing a new valve. Outcomes are shaped by patient selection, valve anatomy, vascular access, heart function, rhythm status, other medical conditions, procedural planning, and the quality of post-procedure care.

The single most important question is whether your symptoms are truly caused by the aortic stenosis. Some patients also have lung disease, coronary artery disease, anaemia, arrhythmias, or simple deconditioning, all of which can produce breathlessness and fatigue of their own. Treating the valve may help substantially, but the other conditions need managing too if the functional result is to match expectations.

The anatomy of the valve and its surroundings is central to planning. Heavy calcium, a bicuspid valve shape, a small valve ring, low-lying coronary arteries, an enlarged aorta, or narrow peripheral arteries each change the procedural strategy. Detailed imaging exists to surface these issues before you enter the procedure room, not during the case.

Heart rhythm is another key consideration. Some patients already have conduction disease, such as bundle branch block, before TAVI. Because the replacement valve sits close to the heart’s electrical pathways, a pacemaker may be needed in some cases afterwards. Careful monitoring in the first days identifies rhythm problems early, when they are easiest to manage.

Kidney function matters as well, because CT scanning and angiographic imaging use contrast dye. In patients with chronic kidney disease, the team may adapt imaging protocols, hydration strategies and monitoring to reduce the strain. Patients with a history of stroke, bleeding, or vascular disease similarly require tailored planning rather than a standard pathway.

Medication management after TAVI is individualised. Many patients need antiplatelet or anticoagulant therapy, particularly those with atrial fibrillation, coronary stents, or other clotting risks. The right regimen balances protection against clots forming on the new valve against the risk of bleeding, and it is decided and adjusted by the treating cardiologist based on your specific situation.

Long-term results also depend on overall cardiovascular care. Blood pressure control, diabetes management, cholesterol treatment, smoking cessation, appropriate exercise, dental hygiene — which matters because dental infections can seed heart valves — and follow-up echocardiography all play a role. TAVI treats the narrowed valve; it does not replace the need for ongoing heart care. For patients managing diabetes, that preparation includes reviewing glucose control, medication timing and contrast-related precautions with the treating team before the procedure.

How TAVI Care Is Organised for International Patients at Acibadem

Patients travelling from abroad for a valve procedure tend to ask the same reasonable questions. Is the diagnosis correct? Is TAVI actually the right treatment for me, or would surgery serve better? Who reviews the case, and on what evidence? What happens if something unexpected occurs during or after the procedure? How will follow-up work once I am home?

At Acibadem, TAVI care is organised around a multidisciplinary cardiovascular model. Cases are reviewed by physicians from the relevant specialties — interventional cardiology, cardiovascular surgery, cardiac imaging, anaesthesiology and intensive care, with other disciplines added when needed. This team structure matters most in complex valve disease, where the better treatment can hinge on subtle differences in anatomy and surgical risk that no single specialty sees in full.

Personalised planning is central, and it cuts both ways. Some patients who arrive expecting TAVI are better served by surgical valve replacement. Others need coronary treatment before or alongside the valve. Some require optimisation of heart failure, rhythm control, kidney function or infection risk before any valve procedure is sensible. A responsible programme does not treat TAVI as a default; it determines whether the procedure is appropriate for this patient, and if so, how to perform it as safely as the anatomy allows.

Second-opinion reviews follow the same logic. Available echocardiograms, CT scans, angiography images, operative reports and physician notes are examined; where imaging is incomplete or outdated, repeat testing is recommended rather than guessed around. The purpose is not only to confirm eligibility but to explain the options clearly enough that patients can decide together with their families and their own physicians.

Practical coordination sits alongside the clinical work. Acibadem International provides support in more than 20 languages, assisting with medical record transfer, appointment planning, interpretation, hospital admission, discharge coordination and communication with clinical teams — the practical layer of a treatment pathway abroad, from preparation through to the journey home.

After discharge, travel guidance is individualised: activity limits, wound care, medications, what to watch for, and when your local cardiologist should next see you. The handover back to your home physician — with reports, imaging and a clear medication plan — is part of the treatment, not an extra.

Making a Considered Decision

TAVR has changed the treatment landscape for severe aortic stenosis, above all for patients who are not ideal candidates for open-heart surgery. It offers a less invasive way to replace a narrowed aortic valve — but it remains a serious intervention that stands or falls on careful evaluation, precise imaging, expert procedural planning and attentive recovery care.

If you or a family member has been diagnosed with severe aortic stenosis, the questions worth answering next are concrete ones. Has the disease reached the point where valve replacement is needed? Is the anatomy suited to a transcatheter valve, or does surgery serve better? What does the imaging show about access routes, calcium and the coronary arteries? What would recovery and follow-up look like in your specific circumstances? A structured heart-team assessment exists to answer exactly these questions — clarifying the diagnosis, estimating procedural risk, identifying anatomical considerations, and comparing the options honestly. The right choice is the one shaped around the individual patient, not around the procedure.